EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Linker Chemistry in Antibody–Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks

Theeraphop Prachyathipsakul iD, Prachi Gupta iD, Seth K Thayumanavan, Sandhya Vijay, Karuppiah Kannan, S Thayumanavan iD

Bioconjugate Chemistry · 19.08.2026 · 37 (8) · 1507-1515

DOI: 10.1021/acs.bioconjchem.6c00299 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, online erschienen am 23.07.2026. Verfasst von Theeraphop Prachyathipsakul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Massachusetts, Amherst, Massachusetts01003, United States. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents. Die Arbeit nennt 101 Literaturangaben. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the increasing cancer incidence and death tolls worldwide, antibody–drug conjugates (ADCs) have emerged as a promising platform to selectively deliver cytotoxic payloads to cancerous tissues. This platform has the potential to spare patients from off-target effects compared to traditional chemotherapy. Despite the clinical success of some ADCs, many in the pipeline did not even reach the clinical stage. We turn our attention to their linker chemistry that connects the antibody and the drug molecules together. Despite their small size, linkers play a key role in governing the payload release kinetics and location. In this Viewpoint, we collect and discuss a plethora of linkers employed in ADC development, specifically focusing on advancements in antibody modification and linker cleavage chemistries. The choice of linker chemistry has evolved over time, going from stochastically attached non-stimuli-responsive to site-specifically modified cleavable linkers. Then we correlate the linker technologies to their pharmacokinetic outcomes in clinics, followed by a discussion of the upcoming “linker-free” technology for more facile and efficient antibody-conjugated targeted delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntineoplastic AgentsHumansAnimalsNeoplasms

Substanzen

ImmunoconjugatesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, University of Massachusetts, Amherst, Massachusetts01003, United States.
  • Nalam Therapeutics, Amherst, Massachusetts01003, United States.
  • Department of Biomedical Engineering, University of Massachusetts, Amherst, Massachusetts01003, United States.
  • Center of Bioactive Delivery, Institute of Applied Life Science, University of Massachusetts, Amherst, Massachusetts01003, United States.

ORCID-Profile: Theeraphop Prachyathipsakul, Prachi Gupta, S Thayumanavan

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Prachyathipsakul, T., Gupta, P., Thayumanavan, S. K., Vijay, S., Kannan, K., & Thayumanavan, S. (2026). Linker Chemistry in Antibody–Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks. Bioconjugate Chemistry, 37(8), 1507-1515. https://doi.org/10.1021/acs.bioconjchem.6c00299

Vancouver

Prachyathipsakul T, Gupta P, Thayumanavan SK, Vijay S, Kannan K, Thayumanavan S. Linker Chemistry in Antibody–Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks. Bioconjugate Chemistry. 2026;37(8):1507-1515. doi:10.1021/acs.bioconjchem.6c00299

BibTeX
@article{Prachyathipsakul2026,
  author = {Prachyathipsakul, Theeraphop and Gupta, Prachi and Thayumanavan, Seth K and Vijay, Sandhya and Kannan, Karuppiah and Thayumanavan, S},
  title = {Linker Chemistry in Antibody–Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks},
  journal = {Bioconjugate Chemistry},
  year = {2026},
  volume = {37},
  number = {8},
  pages = {1507--1515},
  doi = {10.1021/acs.bioconjchem.6c00299}
}
Kostenlos starten →